SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Purchased by Castleark Management LLC

Castleark Management LLC raised its position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 7.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 78,350 shares of the company’s stock after purchasing an additional 5,300 shares during the quarter. Castleark Management LLC’s holdings in SpringWorks Therapeutics were worth $3,856,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Russell Investments Group Ltd. boosted its holdings in SpringWorks Therapeutics by 49.0% in the 1st quarter. Russell Investments Group Ltd. now owns 170,047 shares of the company’s stock valued at $8,370,000 after purchasing an additional 55,893 shares during the last quarter. Seven Eight Capital LP acquired a new position in SpringWorks Therapeutics in the 4th quarter valued at about $1,544,000. Price T Rowe Associates Inc. MD boosted its holdings in SpringWorks Therapeutics by 48.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,110,462 shares of the company’s stock valued at $202,318,000 after purchasing an additional 1,333,892 shares during the last quarter. Perceptive Advisors LLC raised its stake in shares of SpringWorks Therapeutics by 28.7% in the 4th quarter. Perceptive Advisors LLC now owns 1,957,246 shares of the company’s stock valued at $71,439,000 after acquiring an additional 436,830 shares during the period. Finally, Point72 Asset Management L.P. raised its stake in shares of SpringWorks Therapeutics by 310.7% in the 4th quarter. Point72 Asset Management L.P. now owns 2,162,176 shares of the company’s stock valued at $78,919,000 after acquiring an additional 1,635,722 shares during the period.

SpringWorks Therapeutics Price Performance

SWTX traded down $0.02 during trading hours on Thursday, hitting $35.89. 272,645 shares of the company’s stock were exchanged, compared to its average volume of 965,766. SpringWorks Therapeutics, Inc. has a 12-month low of $18.00 and a 12-month high of $53.92. The firm has a 50 day moving average of $38.65 and a 200 day moving average of $43.45.

SpringWorks Therapeutics (NASDAQ:SWTX) last announced its earnings results on Thursday, May 2nd. The company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.01). The company had revenue of $21.00 million for the quarter, compared to analysts’ expectations of $12.07 million. During the same quarter in the prior year, the firm posted ($1.18) earnings per share. The firm’s revenue for the quarter was up 2000.0% compared to the same quarter last year. On average, research analysts forecast that SpringWorks Therapeutics, Inc. will post -4.62 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $74.00 price target on shares of SpringWorks Therapeutics in a research note on Friday, May 31st. Wedbush reissued an “outperform” rating and issued a $75.00 price target (up from $70.00) on shares of SpringWorks Therapeutics in a research note on Thursday, May 2nd. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $68.83.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.